NCT03944460View on ClinicalTrials.gov

SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
Alzheimer DementiaAlzheimer Disease
Interventions
DRUG

Contraloid

Oral administration of capsules, drug substance or placebo without any excipients.

Trial Locations (1)

52425

Forschungszentrum Jülich, Jülich

Sponsors

Collaborators (1)

NeuroScios, Austria
All Listed Sponsors
collaborator

Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany

UNKNOWN

collaborator

Medical University of Vienna

OTHER

collaborator

NeuroScios, Austria

UNKNOWN

collaborator

Triskelion, The Netherlands

UNKNOWN

collaborator

Fundación Teófilo Hernando, Spain

OTHER

lead

Prof. Dr. Dieter Willbold

OTHER

NCT03944460 - SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate | Biotech Hunter | Biotech Hunter